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Abstract
Background Therapies may be more efficacious when
targeting a patient subpopulation with specific attributes,
thereby enhancing the cost-effectiveness of treatment. In
the CRYSTAL study, patients with metastatic colorectal
cancer (mCRC) were treated with cetuximab plus FOLFIRI
or FOLFIRI alone until disease progression, unaccept-
able toxic effects or withdrawal of consent.
Objective To determine if stratified use of cetuximab
based on genetic biomarker detection improves cost-
effectiveness.
Methods We used individual patient data from CRYSTAL
to compare the cost-effectiveness, cost per life-year (LY)
and cost per quality-adjusted LY (QALY) gained of
cetuximab plus FOLFIRI versus FOLFIRI alone in three
cohorts of patients with mCRC: all randomised patients
(intent-to-treat; ITT), tumours with no detectable muta-
tions in codons 12 and 13 of exon 2 of the KRAS protein
(‘KRAS wt’) and no detectable mutations in exons 2, 3 and
4 of KRAS and exons 2, 3 and 4 of NRAS (‘RAS wt’).
Survival analysis was conducted using RStudio, and a cost-
utility model was modified to allow comparison of the
three cohorts.
Results The deterministic base-case ICER (cost per QALY
gained) was £130,929 in the ITT, £72,053 in the KRAS wt
and £44,185 in the RAS wt cohorts for cetuximab plus
FOLFIRI compared with FOLFIRI alone. At a £50,000
willingness-to-pay threshold, cetuximab plus FOLFIRI has
a 2.8, 20 and 63% probability of being cost-effective for
the ITT, KRAS wt and RAS wt cohorts, respectively,
versus FOLFIRI alone.
Conclusion Screening for mutations in both KRAS and
NRAS may provide the most cost-effective approach to
patient selection.
Key Points for Decision Makers
Adding cetuximab to FOLFIRI is more cost-effective
in patients with metastatic colorectal cancer (mCRC)
and a wild-type RAS gene than in the mCRC
population at large.
At a £50,000 willingness-to-pay threshold,
cetuximab plus FOLFIRI has 63% probability of
being cost-effective among patients with the wild-
type RAS gene compared with a 2.8% probability
among the mCRC population at large.
These results demonstrate potential economic
benefits of personalised medicine based on
biomarker testing.
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article (https://doi.org/10.1007/s40258-018-0395-5) contains supple-
mentary material, which is available to authorised users.
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1 Introduction
Personalised medicine uses information about specific
patient biological attributes and environment to most
effectively prevent, diagnose or treat disease. Biomarker
testing for a particular biological attribute is one way
through which patients may be differentiated [1–4]. The
premise underlying personalised medicine is that therapies
demonstrating a particular therapeutic outcome for an
overall disease population may show greater effect when
targeting a subgroup with a certain set of attributes. Aside
from enabling practitioners to more effectively treat
patients, personalised medicine may also benefit healthcare
systems through enhancing the cost-effectiveness of a
particular treatment [5]. In oncology, biomarker testing and
stratified medicine may allow development of precision
care plans using the most appropriate medication given the
biological status of a patient’s tumour [6]. Improved out-
comes translate directly into improved cost-effectiveness if
the benefit to the patient outweighs the increased costs to
the healthcare system, such as from additional drug
acquisition and administration and biomarker testing costs
[7].
Colorectal cancer (CRC) is one of the most common
cancers in the United Kingdom (UK), with an annual
incidence of about 40,000 patients [8]. CRC is one of
several cancer types associated with overexpression of the
epidermal growth factor receptor (EGFR) signalling path-
way. Signalling through this pathway results in cell pro-
liferation, inhibition of apoptosis, activation of invasion,
metastasis and angiogenesis [9–11]. Based on the role of
EGFR in cancer, anti-EGFR therapy has been introduced as
an approach to reduce intracellular signalling. There are
several molecular components downstream of the EGFR
pathway that help regulate the effects of EGFR stimulation.
The rat sarcoma oncogene (RAS) proteins Kirsten rat sar-
coma viral oncogene homolog (KRAS) and neuroblastoma
RAS viral oncogene homolog (NRAS) are components of
the second-messenger signalling pathway initiated by
EGFR, and they help regulate the cell cycle [9–12]. In
some patients, RAS proteins harbour mutations that render
these proteins unaffected by any changes induced by anti-
EGFR-based treatment [13, 14]. Patients with these muta-
tions can be identified by biomarker testing [12, 15, 16].
Cetuximab is an immunoglobulin G1 monoclonal anti-
body that targets EGFR, and has been licensed since 2008
in combination with 5-fluorouracil and leucovorin plus
oxaliplatin (FOLFOX) and with 5-fluorouracil and leu-
covorin plus irinotecan (FOLFIRI) chemotherapy for first-
line use in patients with metastatic CRC (mCRC). The
pivotal CRYSTAL study was an open-label, randomised,
controlled, multicentre phase 3 trial that compared
FOLFIRI plus cetuximab versus FOLFIRI alone as first-
line therapy for EGFR-expressing mCRC [14, 17, 18].
Study results showed significantly longer progression-free
survival (PFS) with cetuximab plus FOLFIRI compared
with FOLFIRI alone [17]. In the intent-to-treat (ITT)
population, comprising all patients randomised to receive
treatment, the cetuximab-plus-FOLFIRI arm showed a
median overall survival (OS) of 19.9 months compared
with 18.6 months in the FOLFIRI-alone arm, correspond-
ing to a 1.3-month benefit with a hazard ratio (HR) of 0.93
(95% CI 0.81–1.07; P = 0.31) [17]. Based on the role of
the EGFR pathway in mCRC, investigators examined
subpopulations of patients defined by RAS genotype;
specifically, KRAS wild-type (wt) patients (tumours had no
detectable mutations in codons 12 and 13 of exon 2 of
KRAS), and RAS wt patients [meeting KRAS wt criteria
plus no detectable mutations in exons 2 (codons 12 and 13)
of NRAS, 3 (codons 59 and 61) and 4 (codons 117 and
146) of KRAS and NRAS] [14].
When comparing median OS in the cetuximab-plus-
FOLFIRI arm versus the FOLFIRI-alone arm in biomarker-
selected subgroups, patients with a KRAS wt genotype
demonstrated a 3.5-month benefit in median OS [23.5 vs.
20.0 months, respectively; HR, 0.796 (95% CI
0.670–0.946); P = 0.0093] [18], while patients in the RAS
wt subgroup showed an 8.2-month benefit in median OS
[28.4 vs. 20.2 months, respectively; HR, 0.69 (95% CI
0.54–0.88); P = 0.0024] [14]. On the basis of these and
other data demonstrating enhanced efficacy of EGFR
inhibitors in patients with RAS wt tumours, clinical prac-
tise guidelines recommend testing for RAS status prior to
determining first-line treatment for patients with mCRC,
and the indication for cetuximab was updated accordingly
[19, 20].
Economic analyses of the cost-effectiveness of cetux-
imab have been submitted to several UK regulatory bodies
for health technology assessments (HTAs), resulting in
recommendations for restricted use (Table 1). In the cur-
rent study, an objective economic evaluation was per-
formed using CRYSTAL trial cohorts to determine if
stratified use of cetuximab based on genetic biomarker
detection improves cost-effectiveness. This investigation
was based on the hypothesis that treating the popula-
tion(s) that benefit(s) the most should improve the cost-
effectiveness of the intervention. This is the first time a
common model or platform has been used so that the
incremental cost-effectiveness ratios (ICERs) between
three populations can be examined objectively in patients
with mCRC.
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2 Methods
Individual patient data (IPD) from the CRYSTAL study
were obtained from Merck KGaA (Darmstadt, Germany).
All patients in the CRYSTAL study provided written and
oral informed consent [17]. Results were categorised into
three cohorts: the ITT population, the KRAS wt subgroup
and the RAS wt subgroup (defined above) [14], comparing
cetuximab plus FOLFIRI versus FOLFIRI alone. FOLFOX
was not investigated, because the phase 2 clinical trial that
compared the use of cetuximab in combination with
FOLFOX versus FOLFOX alone (OPUS) had a smaller
patient population, and, thus, greater volatility around the
results [26]. Tumour genotypes were determined using a
polymerase-chain-reaction technique on DNA extracted
from tumour-biopsy specimens. Screening for KRAS
mutations in codons 12 and 13 was performed initially and
then samples determined as KRAS wt were subsequently
screened for the RAS genotype [14, 17].
For the cost-effectiveness comparison, a proprietary,
validated cost-utility model was used to compare cetux-
imab-based first-line treatment regimens with irinotecan-
based chemotherapy for patients with mCRC based on
PFS, adverse events (AEs) and resource usage. Utilities
were obtained from quality-of-life (QOL) data collected
during the original CRYSTAL trial [27]. The model was
created using a UK National Health Service (NHS) per-
spective; therefore, only direct costs to the NHS were
included. The model was developed in Microsoft Excel
with Visual Basic codes to conduct one-way sensitivity
analyses (OWSA) and probabilistic sensitivity analyses
(PSA) for appropriate pairwise comparisons [28]. The core
of the model is a state-transition Markov cohort method
developed to simulate patient outcomes and costs for first
and subsequent lines of oncology treatment, including
long-term survival after a successful curative resection of
liver metastases. As opposed to area-under-the-curve
analyses, this model is a Markov state and transition model
with the probabilities of transitions dependent on time from
the beginning of treatment of cohort and on time in state.
This means the probability of transition from second-line to
third-line therapy is dependent on the time of progression
from first-line therapy to second-line therapy. To apply
these time-dependent transition probabilities for this
sequence of treatments, the model uses tunnel states. This
model structure is based on previous models submitted to
HTA bodies and subsequently published [29, 30]. To pro-
vide a distribution around each parameter, an upper and
lower limit was generated by using the 0.025 percentile as
a lower bound and the 0.975 percentile as an upper bound
of the relevant variable. The specific model used was based
on an earlier model developed to demonstrate the cost-
effectiveness in the RAS wt cohort alone (see Ref. [29]).
The current model was modified so that all three cohorts
(ITT, KRAS wt and RAS wt) within the CRYSTAL study
could be analysed together. The main adaptive changes
within the current model affect a patient’s progression
through the first-line heath state, the curative resection
rates and the frequency of AEs between cohorts.
A disease-modelling approach (assuming the PFS ben-
efits of first-line cancer treatments translate directly into
OS benefits) was selected to examine costs and benefits
outside the trial period to compare cohorts over a longer
time horizon than the study provided. This model was
previously assessed by a National Institute for Health and
Care Excellence (NICE) Evidence Review Group (ERG)
[22]. The time horizon was set to 10 years, which was
considered reasonable to capture all costs and benefits,
including those of patients who receive curative surgery,
and is consistent with previous HTA submissions
(Table 1). The NICE discounting policy was followed,
which is to apply a 3.5% discount rate for costs and
Table 1 Previous cetuximab submissions for UK health technology assessment
Date/reference HTA group HTA ID Population Outcome
04 Apr 2009 [21] SMC 543/09 First-line in all patients with KRAS wt mCRC Not recommended
01 Aug 2009 [22] NICE TA176 First-line in subgroup of patients with
liver-limited KRAS wt mCRC
Recommended for restricted use
08 Feb 2010 [21] SMC 543/09/Resubmission First-line in subgroup of patients with
liver-limited KRAS wt mCRC
Recommended for restricted use
12 Jan 2015 [23] SMC 1012/14 First-line in all patients with RAS wt mCRC Recommended for restricted use
24 Feb 2016 [24] AWMSG 4315 First-line in patients with RAS wt mCRC Recommended for restricted use
March 2017 [25] NICE Pending First-line in RAS wt mCRC in combination
with FOLFOX or FOLFIRI
Recommended
AWMSG All Wales Medicines Strategy Group, FOLFIRI 5-fluorouracil and leucovorin plus irinotecan, FOLFOX 5-fluorouracil and leucovorin
plus oxaliplatin, HTA health technology assessment, ID identification, KRAS Kirsten rat sarcoma viral oncogene homolog, mCRC metastatic
colorectal cancer, NICE National Institute for Health and Care Excellence, RAS rat sarcoma oncogene, SMC Scottish Medicines Consortium, wt
wild type
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benefits. We also made no distinction between no resection
and unsuccessful resection, because it may only become
apparent after initiation of treatment if surgery is an option
[31]. The model was updated by constructing the time-to-
event data from the IPD for the ITT, KRAS wt and RAS wt
cohorts. Model inputs are provided in Table S1. These
parameters were then used to generate the transition
probability for the Markov cycles. Adverse events
(Table S2) and resection rates (Table S3) were also col-
lated. The risk of progression from first-line treatment was
applied in the model using the Weibull parametric
extrapolations of the time to progression. R and RStudio
(version 3.1.2) were used to derive the numerical coeffi-
cients for this distribution. The IPD PFS time in the data
was converted to weeks to match the transition cycles
within the model and uploaded into RStudio. The Weibull
parametric model was fitted using ‘survreg()’ [32], then
outputs from RStudio created from the model were entered
to determine new extrapolation distributions for each of the
three cohorts. The proportional hazards assumption was
made for the Kaplan–Meier data for the treatment arms
from the CRYSTAL trial. Based on experience that the
Weibull model was the best fit for this data, further para-
metric survival analysis was considered to be unnecessary
as the objective was to maintain consistency between the
core model parameters to compare like with like.
Patients entering the model started in the first-line
therapy health state, then either underwent curative resec-
tion of liver metastases and entered the postresection health
state or progressed to the second-line treatment health
state, then to the third-line health state (Fig. 1). Patients
received best supportive care as third-line treatment. In the
treatment and control arms, second- and third-line pro-
gression was not adjusted within the model. It was assumed
that the same principles of further progression in the sec-
ond line, and survival in the third line, were followed for all
patients who progressed at different times from the start of
first-line treatment. It was also assumed that the survival
probability following curative resection was identical for
all treatment arms, and survival estimates of curative sur-
gery were based on those reported by Adam et al. [33].
Grade 3/4 AEs from both arms of the three cohorts were
sourced and extracted from the CRYSTAL publications
[14, 17, 18] and clinical study reports and entered into the
model. Treatment costs (acquisition and administration) for
all the health states were derived from the 2013 British
National Formulary and UK National Reference Costs
(Table S4). AE costs depended on the assumption that there
would be an associated outpatient or inpatient visit, and
included cost of drugs and outpatient visits. For the ITT
analysis, costs associated with biomarker testing were
removed from the model as this population would not have
been stratified before treatment, but costs were included
within the other cohorts. Sensitivity and specificity analysis
of the biomarker testing was not conducted, as all patients
were presumed to be correctly stratified in the post hoc
analysis because these biomarker techniques have high
technical accuracy [34].
Cost-effectiveness was measured in terms of costs per
life-year (LY) gained and per quality-adjusted life-year
(QALY) gained. Both OWSA and PSA were evaluated
using standard methods [35]. The PSA was set at 2000 runs
and the distributes for the majority of parameters are pre-
sented in Table S5. For the OWSA, where the standard
error was missing for some variables, it was assumed to be
10% of the mean value. This was held consistent between
all cohorts. As an alternative to comparing the resulting
ICERs between groups, two willingness-to-pay (WTP)
thresholds were also considered in the model at £30,000
and £50,000 (£30,000 based on the upper level of the NICE
WTP threshold for the UK, and £50,000 when end-of-life
criteria are considered appropriate for a technology) [36].
3 Results
Baseline characteristics were generally consistent between
the ITT, RAS wt and KRAS wt populations, as described
previously [14, 17, 18]. Results of the cost-effectiveness
analysis of the three CRYSTAL cohorts are presented in
Table 2. In the deterministic base-case ICER cost per LY
gained, results for cetuximab plus FOLFIRI versus FOL-
FIRI alone were £98,742 for the ITT, £55,242 for
Fig. 1 Demonstration of how patients move between the different
health states. Patients entered the model in the first-line therapy health
state, then either underwent curative resection of liver metastases and
entered the postresection health state or progressed to the second-line
treatment health state, then to the third-line health state
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the KRAS wt and £34,171 for the RAS wt cohorts,
respectively. The results for the deterministic base-case
ICER cost per QALY gained were £130,929 for the ITT,
£72,053 for the KRAS wt and £44,185 for the RAS
wt cohorts. The analysis output demonstrated that the
cetuximab arm resulted in an improvement of 0.16 LYs
and 0.12 QALYs among the ITT cohort compared with
0.29 LYs and 0.22 QALYs for KRAS wt and 0.45 LYs and
0.35 QALYs for RAS wt. The incremental cost of treat-
ment per patient changed slightly in the ITT (£15,802),
KRAS wt (£15,907) and RAS wt (£15,495) groups, which
was mainly driven by the increasing proportion of patients
who received curative surgery and no longer required
second- or third-line chemotherapy. Together these data
suggest that the RAS wt group was the most cost-effective
of the cohorts.
The tornado diagrams in Figure 2 show the results of the
OWSA on the deterministic base-case ICER for the
cetuximab-plus-FOLFIRI versus FOLFIRI-alone compar-
isons. In all tornado diagrams, the HR of progression from
first-line for cetuximab plus FOLFIRI compared with
FOLFIRI and the number of months on treatment had the
most impact on the model. Resection rates, body surface
area and unit cost of cetuximab also had a substantive
effect on the ICER. In the ITT cohort, increasing the HR
from the base-case value of 0.80 to the upper bound of
1.196 resulted in an ICER of £878,390. Reducing this HR
to its lower bound (0.539) generated an ICER of £65,734
(Fig. 2a). Variation in the duration of treatment had a large
impact on the ICER. Assuming that the lower bound of this
variable (3.51 months) generated an ICER of £78,461, a
treatment regimen lasting 8.03 months resulted in an ICER
of £176,003. Resection rates also had a considerable effect
on the ICER: the lower rate (0.039) of the cetuximab-plus-
FOLFIRI ITT cohort increased the ICER to £187,890, and
the higher resection rate (0.087) lowered the ICER to
£93,904. In the KRAS wt group, increasing the HR from a
base-case value of 0.645 to the upper bound of 0.936
resulted in an ICER of £177,050. Reducing the HR to its
lower bound (0.444) generated an ICER of £42,153
(Fig. 2b). Variation in the duration of treatment had a large
impact on the ICER in this cohort as well, assuming that
the lower bound of this variable (3.51 months) generated
an ICER of £42,796, while a treatment regimen lasting
8.03 months resulted in an ICER of £98,675. The unit cost
of cetuximab and the average body surface area had a
slightly greater impact than the resection rates on the
deterministic base-case ICER in this group. In the RAS wt
group, increasing the HR from the base-case value of 0.564
to the upper bound of 0.782 resulted in an ICER of
£83,362. Reducing this HR to its lower bound (0.407)
generated an ICER of £27,893 (Fig. 2c). As in the ITT and
KRAS wt cohorts, variation in the duration of treatment
also had a large impact on the ICER among patients in the
RAS wt cohort, assuming that the lower bound of this
variable (3.51 months) generated an ICER of £25,626,
while a treatment regimen lasting 8.03 months resulted in
an ICER of £61,409. Unit cost of cetuximab and the
average body surface area had a greater impact than the
resection rates on the deterministic base-case ICER (re-
section rates decreased to sixth place).
Probabilistic sensitivity analysis results are shown on
cost-effectiveness scatter plots (Fig. 3) and by cost-effec-
tiveness acceptability curves (CEAC; Fig. 4). To test
overall model uncertainty, results for the £30,000 and
£50,000 WTP thresholds are shown. The scatter plots
indicate that treatment with cetuximab plus FOLFIRI ver-
sus FOLFIRI alone is costlier but also more effective
Table 2 Incremental cost-effectiveness results
Costs (£) LYs gained QALYs gained ICER (cost per LY) ICER (cost per QALY)
ITT population
Cetuximab ? FOLFIRI 47,643 2.05 1.50
FOLFIRI 31,840 1.89 1.38
Increment 15,802 0.16 0.12 98,742 130,929
KRAS wt cohort
Cetuximab ? FOLFIRI 47,712 2.29 1.69
FOLFIRI 31,840 2.00 1.47
Increment 15,907 0.29 0.22 55,242 72,053
RAS wt cohort
Cetuximab ? FOLFIRI 47,168 2.54 1.89
FOLFIRI 31,673 2.09 1.54
Increment 15,495 0.45 0.35 34,171 44,185
FOLFIRI 5-fluorouracil, leucovorin and irinotecan, ICER incremental cost-effectiveness ratio, ITT intent-to-treat, KRAS Kirsten rat sarcoma viral
oncogene homolog, LY life-year, QALY quality-adjusted life-year, RAS rat sarcoma oncogene, wt wild type
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(Fig. 3). The least favourable distribution occurred in the
ITT cohort (Fig. 3a), where some of the simulations fell
into the northwest quartile, where cetuximab plus FOLFIRI
would be considered costlier and less effective than FOL-
FIRI alone. ICER plots shift further east in the quartile as
the cohorts move from ITT to KRAS wt (Fig. 3b) and RAS
wt (Fig. 3c) based on increased efficacy of cetuximab in
these patient groups and result in an increasing proportion
of the ICERs below the WTP line. The clusters become
more diffuse, indicating more uncertainty as numbers of
patients in the sample are reduced. Using a £50,000 WTP
threshold, the RAS wt cohort would still have the highest
probability of being cost-effective compared with the other
cohorts (Fig. 3). Results of CEACs indicate the probability
that the treatment strategy of each cohort is cost-effective
at different WTP threshold per QALY thresholds. Figure 4
shows that, at the £30,000 WTP threshold, cetuximab plus
FOLFIRI in the ITT cohort has a 0% probability of being
cost-effective, and, in the KRAS wt cohort, there is only a
5% chance that it is cost-effective. However, in the RAS wt
cohort, at the £30,000 limit, there is a 15% probability that
cetuximab plus FOLFIRI versus FOLFIRI alone in this
group is cost-effective. The probability that the treatment
strategy of each population is cost-effective at a WTP
threshold of £50,000 is\ 5% for the ITT population, 20%
for the KRAS wt group and 63% for the RAS wt group.
4 Discussion
Research to date has shown that the majority of treatments
prescribed for various disease conditions are effective in
\ 60% of treated patients (25–30% in oncology), under-
scoring the potential (and need) for efficiency gains in
healthcare delivery [37]. Stratified medicine is a new
approach that may improve medical outcomes for the
patient and the healthcare system by matching therapies to
specific patient populations using clinical biomarkers and
diagnostics. Stratified medicine can enhance patient care
through the development and administration of safer and
more effective drugs delivered with a greater chance of
successful treatment. Additionally, more accurate targeting
of patients with the most effective medication will decrease
the burden on healthcare systems by more efficient
healthcare delivery [37]. Despite the potential for stratified
medicine to foster greater success in treatment outcomes, it
is currently not widely used, due, in part, to scientific
barriers, economic concerns and difficulties in securing
coverage and adequate reimbursement. Many currently
available tests do not have the sensitivity required to
identify clinically meaningful differences between patient
populations to facilitate effective stratification [37].
Healthcare interventions with demonstrated clinical
efficacy and marketing authorisation may not ultimately be
used in the originally intended population, as access to the
healthcare system may be decreased due to a high ICER.
However, a treatment that is not used cannot offer a benefit
to the patient or the healthcare system. The aim of this
study was to investigate this question through an economic
evaluation of the three cohorts (ITT, KRAS wt and RAS
wt) from the CRYSTAL study and determine if the strat-
ification of cetuximab plus FOLFIRI versus FOLFIRI by
biomarker status improves its cost-effectiveness. Based on
our results, among patients with mCRC treated with anti-
eGFR therapy, treatment of patients in the RAS wt cohort
demonstrated the most cost-effectiveness of the
three cohorts.
Our results are consistent with those of previous studies
that support the notion that targeting patients with RAS wt
tumours is more cost-effective than treating patients with
KRAS wt tumours; however, our study is unique in that it
compares three cetuximab populations at once. The FIRE-3
trial [38, 39] compared cetuximab plus FOLFIRI with
bevacizumab plus FOLFIRI (not FOLFIRI alone) and
compared only the KRAS wt versus the RAS wt popula-
tions. In that study, first-line treatment alone and not
sequential use of the products likely drove the outcome
[40], whereas the CRYSTAL data demonstrated a clear
implication that cetuximab drives the improved clinical
benefit and cost-effectiveness in targeting therapy. Addi-
tionally, Wen et al. [39] discussed the added costs of RAS
screening versus KRAS screening and displayed results in
quality-adjusted life-months. Kircher et al. [41] found that
the increased societal cost of expanded RAS testing versus
standard approved KRAS exon 2 testing was inconse-
quential compared with the savings achieved by not treat-
ing the 18% of patients who harbour additional RAS
mutations (beyond exon 2) with anti-EGFR therapy.
Another study revealed that additional savings may be
obtained when testing for mutations in the BRAF gene is
added to KRAS screening [42].
In this study, the economic analysis revealed that vari-
ation in incremental cost was driven by the changing pro-
portion of patients in the cetuximab-plus-FOLFIRI or the
bFig. 2 One-way sensitivity analysis results. Results of the OWSA on
the deterministic base-case ICER for the cetuximab-plus-FOLFIRI
versus FOLFIRI-alone comparisons for the a ITT cohort, b KRAS wt
cohort and c RAS wt cohort. Values provided for each entry represent
the upper and lower limits generated by using the 0.025 percentile as
a lower bound and the 0.975 percentile as an upper bound of the
relevant variable. BSA body surface area, BSC best supportive care,
FOLFIRI 5-fluorouracil and leucovorin plus irinotecan, HR hazard
ratio, ICER incremental cost-effectiveness ratio, ITT intent-to-treat,
KRAS Kirsten rat sarcoma viral oncogene homolog, OWSA one-way
sensitivity analysis, PD progressive disease, PF progression-free,
QALY quality-adjusted life-year, RAS rat sarcoma oncogene
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Fig. 3 Probabilistic sensitivity
analysis results on cost-
effectiveness scatter plots. To
test overall model uncertainty,
results for the £30,000 (beige
dotted line) and £50,000 (green
dotted line) WTP thresholds are
shown. Point estimates,
represented by dots beneath
each dotted line, reflect
simulations falling under each
WTP threshold. Results are
presented for the a ITT,
b KRAS wt and c RAS wt
cohorts. ITT intent-to-treat,
KRAS Kirsten rat sarcoma viral
oncogene homolog, QALY
quality-adjusted life-year, RAS
rat sarcoma oncogene, wt wild
type, WTP willingness to pay
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FOLFIRI-alone arms who received curative surgery and no
longer required second- or third-line chemotherapy. Even
with the costs of biomarker testing considered, the RAS wt
cohort had the lowest overall costs of treatment in the
cetuximab arm and the lowest incremental cost of treat-
ment of all the groups.
The OWSA model was particularly sensitive to the time
spent in first-line progression. It could be determined from
the OWSA that the variables around the hazard function in
first-line progression (derived from the Weibull distribu-
tion) determine the greatest variation around the base-case
ICER. This variation was particularly large in the ITT
group, as the upper-bound HR crossed above 1.0. The HR
of progression and the number of months on treatment
were the variables that had the most impact on the model.
In the tornado diagrams, acquisition costs associated with
cetuximab are among the largest determinants of the
ICERs; however, overall, the relative influence of variables
on the ICER changes between the groups. Results of our
PSA analysis support the OWSA findings. The shift in the
ICER pointed toward greater benefit, and the increasing
proportion below the WTP thresholds visually demon-
strates the improving ICERs as the sample size decreases
from the ITT and KRAS wt to RAS wt cohorts due to
extended restriction of the population of interest based on
biomarkers. In the ITT scatter plot, modelled observations
are located in the northwest quadrant, representing a level
of unfavourability in the ITT group. In these scenarios,
cetuximab treatment would not be beneficial in this small
proportion of patients and may cause harm. Additionally, it
should be noted that even targeting therapy by treating
RAS wt patients still results in a relatively low cost-ef-
fectiveness probability of 63%.
Considering the findings of our study, it should be noted
that our results may have been limited by the fact that post
hoc analysis or retrospective auditing of clinical studies is
not generally considered the best source of evidence due to
risks associated with bias. Additionally, a disease-mod-
elling approach was used (assuming the PFS benefits of
first-line cancer treatments translate directly into OS ben-
efits), and in this evaluation parametric curves were fitted
to the PFS data. In the case of the CRYSTAL study and
subsequent analysis, the PFS results do transform into OS
gains. However, for completion, repeating the analysis
using the OS data would be the next logical step. This may
have an impact on the final deterministic ICER results, but
it should not alter the cost-effective trends between the
cohorts and it is likely to result in a similar conclusion.
5 Conclusions
Targeting therapy to patients based on a genetic biomarker
can notably decrease the ICER, which demonstrated that
the increase in benefit to patients did outweigh the
Fig. 4 Cost-effectiveness acceptability curves for the probabilistic
sensitivity analysis. Dotted lines show probabilities for each cohort at
the £30,000 and £50,000 WTP thresholds. Note, at the £30,000 WTP
threshold, cetuximab plus FOLFIRI versus FOLFIRI alone had a 0%
probability of being cost-effective for the ITT cohort (red line), 5% for
the KRAS wt cohort (green line) and 15% for the RAS wt cohort (blue
line). At the £50,000 WTP threshold, the probability that the treatment
strategy is cost-effective was\ 5% for the ITT, 20% for the KRAS wt
and [ 60% for the RAS wt cohorts. FOLFIRI 5-fluorouracil and
leucovorin plus irinotecan, ITT intent-to-treat, KRAS Kirsten rat
sarcoma viral oncogene homolog, QALY quality-adjusted life-year,
RAS rat sarcoma oncogene, wt wild type, WTP willingness to pay
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increased costs to the healthcare system. The base-case
deterministic ICER results demonstrated that the ICER
declined as the patient population was stratified for the
RAS biomarker. The improved ICER corresponded with
the increase in survival benefit from cetuximab seen for
those patients with the tumour biomarker (KRAS or RAS).
The RAS wt cohort had the lowest ICER; therefore,
cetuximab plus FOLFIRI was the most cost-effective ver-
sus FOLFIRI alone in this subgroup at a WTP threshold of
£50,000.
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